Entresto and Lomotil drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Entresto (sacubitril; valsartan) and Lomotil (atropine sulfate; diphenoxylate hydrochloride). Common drug interactions include death among females and platelet count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Entresto and Lomotil. It is created by eHealthMe based on reports of 44 people who take the same drugs from the FDA, and is updated regularly.

What is Entresto?

Entresto has active ingredients of sacubitril; valsartan. eHealthMe is studying from 126,629 Entresto users. Check the latest studies of Entresto.

What is Lomotil?

Lomotil has active ingredients of atropine sulfate; diphenoxylate hydrochloride. It is often used in diarrhea. eHealthMe is studying from 19,184 Lomotil users. Check the latest studies of Lomotil.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

44 people who take Entresto and Lomotil together, and have interactions are studied.

What are the common drug interactions of Entresto and Lomotil, by gender? *:

female:

Death
Fatigue (feeling of tiredness)
Dyspnoea (difficult or laboured respiration)
Dyspnoea exertional (breathlessness or shortness of breath)
Oedema peripheral (superficial swelling)
Pruritus (severe itching of the skin)
Rash
Arteriosclerosis (thickening and hardening of arteries)
Bacteraemia (presence of bacteria in the blood)
Bacterial infection

male:

Platelet count decreased
Fatigue (feeling of tiredness)
Cardiac failure
Dehydration (dryness resulting from the removal of water)
Muscular weakness (muscle weakness)
Pain
Asthenia (weakness)
Cataract (clouding of the lens inside the eye)
Decreased appetite
Dysphonia (speech disorder attributable to a disorder of phonation)

What are the common drug interactions of Entresto and Lomotil, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Fatigue (feeling of tiredness)
Cardiac failure
Muscular weakness (muscle weakness)
Splenomegaly (enlargement of spleen)
Asthenia (weakness)
Cataract (clouding of the lens inside the eye)
Decreased appetite
Dysphonia (speech disorder attributable to a disorder of phonation)
Hypertension (high blood pressure)
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)

What are the existing conditions these people have? *

Systemic Mastocytosis (a condition caused by the accumulation of mast cells in more than one part of the body): 12 people, 27.27%
Pain: 4 people, 9.09%
Multiple Myeloma (cancer of the plasma cells): 4 people, 9.09%
Splenomegaly (enlargement of spleen): 3 people, 6.82%
Insomnia (sleeplessness): 3 people, 6.82%
High Blood Cholesterol: 3 people, 6.82%
Diabetes: 3 people, 6.82%
Cardiac Failure: 3 people, 6.82%
Breast Cancer: 3 people, 6.82%
Bipolar I Disorder (mood disorder that is characterized by at least one manic or mixed episode): 3 people, 6.82%

* Approximation only. Some reports may have incomplete information.

Do you take Entresto and Lomotil?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously